Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for Americans are injecting themselves with unproven peptides 6abc Philadelphia RFK Jr. promotes peptides. Now the FDA weighs easing limits on the unproven chemicals The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York